Algernon Financial Statements From 2010 to 2024
| AGNPF Stock | USD 0.06 0 3.16% |
Check Algernon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Algernon Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Algernon financial statements analysis is a perfect complement when working with Algernon Pharmaceuticals Valuation or Volatility modules.
Algernon |
Algernon Pharmaceuticals OTC Stock Shares Owned By Insiders Analysis
Algernon Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Algernon Pharmaceuticals Shares Owned By Insiders | 1.70 % |
Most of Algernon Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Algernon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.7% of Algernon Pharmaceuticals are shares owned by insiders. This is 88.8% lower than that of the Healthcare sector and 88.01% lower than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 83.15% higher than that of the company.
Algernon Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Algernon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Algernon Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Algernon Pharmaceuticals competition to find correlations between indicators driving Algernon Pharmaceuticals's intrinsic value. More Info.Algernon Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Algernon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Algernon Pharmaceuticals Financial Statements
Algernon Pharmaceuticals stakeholders use historical fundamental indicators, such as Algernon Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Algernon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Algernon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Algernon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Algernon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada. Algernon Pharmaceuticals is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Algernon OTC Stock
Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.